Skip to main content
SpringerLink
Log in

Crizotinib: risk of vision disorders in paediatric patients

  • News item
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Xalkori (crizotinib) - Important Safety Information from Pfizer Healthcare Ireland as approved by the HPRA Internet Document : 17 Nov 2022. Available from: URL: http://bit.ly/3V44p4V

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Crizotinib: risk of vision disorders in paediatric patients. Reactions Weekly 1934, 1 (2022). https://doi.org/10.1007/s40278-022-28382-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-022-28382-x

Search

Navigation